4 completed, 2 not yet recruiting, 1 unknown. 7 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Not yet recruiting 2, Unknown 1 |
| Phase 1 | 3 | Not yet recruiting 2, Completed 1 |
| Phase 3 | 2 | Completed 2 |
Follow Gastrointestinal Symptoms: new trials by email Literature Review of Gastrointestinal Symptoms trials Research Report on Gastrointestinal Symptoms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Single and Combination Lipase Dietary Supplements to Increase Fatty Acid Absorption in Generally Health Adults THRIVE4U™ TG Lipase, THRIVE4U™ Spectrum Lipases, Placebo - Digestive Symptoms, Gastrointestinal Symptoms | Phase 1 / Phase 2 | Not yet recruiting | Danisco | 50 | 2026-10-01 | 2026-10-23 |
| The Effect of Daily Supplementation With Humiome® Post LB on Gastrointestinal Symptoms in Female Athletes Postbiotic, Placebo - Healthy Adult Females, Gastrointestinal Symptoms | Phase 1 / Phase 2 | Not yet recruiting | Liverpool John Moores University | 100 | 2026-01-01 | 2026-01-27 |
| The Efficacy of Probiotics to Reduce Antepartum Group B Streptococcus Colonization. Florajen3 - Group B Streptococcus Carrier in Childbirth, Gastrointestinal Symptoms | Phase 2 | Unknown | Marquette University | 109 | 2019-02-01 | 2024-03-21 |
| Combination Probiotic: BB-12 With LGG (Different Doses) in Treating Children With Autism Spectrum Disorder BB-12 with LGG (Higher Dose), Placebo, BB-12 with LGG (Lower Dose) - Autism Spectrum Disorder, Gastrointestinal Symptoms | Phase 1 / Phase 2 | Completed | The University of Texas Health Science Center, Houston | 100 | 2016-05-01 | 2026-09-14 |
| Probiotic Supplementation Among Adults With Recurrent Gastrointestinal Symptoms Probiotic dietary supplement (Trenev Trio®), placebo - Gastrointestinal Symptoms, Bloating | Phase 2 / Phase 3 | Completed | University of Maryland, Baltimore | 80 | 2014-12-01 | 2021-09-14 |
| A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System GanedenBC30, GBI-30, PTA-6086, Placebo - HIV Infection, Gastrointestinal Symptoms | Phase 2 | Completed | AIDS Healthcare Foundation | 24 | 2010-08-01 | 2021-01-13 |
| Effect of Bifidobacterium Lactis HN019 on Colonic Transit Time and Digestive Symptoms Bifidobacterium lactis HN019, Placebo - Gastrointestinal Symptoms | Phase 2 / Phase 3 | Completed | Fonterra Research Centre | 100 | 2009-06-01 | 2010-07-28 |
Abdominal Pain (1) · Acquired Immunodeficiency Syndrome (1) · Autism Spectrum Disorder (1) · Constipation (1) · Diarrhea (1) · Dyspepsia (1) · HIV Infections (1) · Mucopolysaccharidosis IV (1)
Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Signs and Symptoms, Digestive (2) · Blood-Borne Infections (1) · Carbohydrate Metabolism, Inborn Errors (1) · Child Development Disorders, Pervasive (1) · Communicable Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1) · Genetic Diseases, Inborn (1) · Genital Diseases (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Infections (1) · Lentivirus Infections (1)
Probiotics (2) · exopolysaccharide biopolymer, Bacillus coagulans (1) · maltodextrin (1)
AIDS Healthcare Foundation (1) · Danisco (1) · Fonterra Research Centre (1) · Liverpool John Moores University (1) · Marquette University (1) · The University of Texas Health Science Center, Houston (1) · University of Maryland, Baltimore (1)
United States (3) · Canada (1) · United Kingdom (1)
Chris D'Adamo, PhD (1) · J Marc RHoads, MD (1) · Lisa C Hanson, PhD (1) · Philip Waller, MD (1) · Zamir J Latif, PharmD (1)
R01HD095158 (1)